162 related articles for article (PubMed ID: 29037255)
1. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.
Carvajal-Hausdorf DE; Mani N; Velcheti V; Schalper KA; Rimm DL
J Immunother Cancer; 2017 Oct; 5(1):81. PubMed ID: 29037255
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
5. High tumor-infiltrating FoxP3
Qian F; Qingping Y; Linquan W; Xiaojin H; Rongshou W; Shanshan R; Wenjun L; Yong H; Enliang L
Eur J Surg Oncol; 2017 Jul; 43(7):1258-1264. PubMed ID: 28214052
[TBL] [Abstract][Full Text] [Related]
6. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of T lymphocytes infiltration in breast cancer].
Yu HM; Jiao SC; Yang JL; Wang JD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):199-206. PubMed ID: 23643010
[TBL] [Abstract][Full Text] [Related]
8. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
9. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.
Mahmoud SM; Paish EC; Powe DG; Macmillan RD; Lee AH; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 May; 127(1):99-108. PubMed ID: 20556505
[TBL] [Abstract][Full Text] [Related]
11. A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.
Greene LI; Bruno TC; Christenson JL; D'Alessandro A; Culp-Hill R; Torkko K; Borges VF; Slansky JE; Richer JK
Mol Cancer Res; 2019 Jan; 17(1):131-139. PubMed ID: 30143553
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.
Ma WJ; Wang X; Yan WT; Zhou ZG; Pan ZZ; Chen G; Zhang RX
World J Gastroenterol; 2018 May; 24(20):2181-2190. PubMed ID: 29853736
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.
Mani NL; Schalper KA; Hatzis C; Saglam O; Tavassoli F; Butler M; Chagpar AB; Pusztai L; Rimm DL
Breast Cancer Res; 2016 Jul; 18(1):78. PubMed ID: 27473061
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers.
Feng X; Tang R; Zhang R; Wang H; Ji Z; Shao Y; Wang S; Zhong T; Gu Y; Meng J
J Cell Mol Med; 2020 May; 24(9):5238-5248. PubMed ID: 32227579
[TBL] [Abstract][Full Text] [Related]
15. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.
Horn T; Laus J; Seitz AK; Maurer T; Schmid SC; Wolf P; Haller B; Winkler M; Retz M; Nawroth R; Gschwend JE; Kübler HR; Slotta-Huspenina J
World J Urol; 2016 Feb; 34(2):181-7. PubMed ID: 26055646
[TBL] [Abstract][Full Text] [Related]
16. IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer.
Kiyozumi Y; Baba Y; Okadome K; Yagi T; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
Ann Surg; 2019 Jun; 269(6):1101-1108. PubMed ID: 31082908
[TBL] [Abstract][Full Text] [Related]
17. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.
Heeren AM; van Dijk I; Berry DRAI; Khelil M; Ferns D; Kole J; Musters RJP; Thijssen VL; Mom CH; Kenter GG; Bleeker MCG; de Gruijl TD; Jordanova ES
Front Immunol; 2018; 9():1598. PubMed ID: 30050535
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of immune classification using IDO1 expression in extrahepatic bile duct carcinoma.
Noh BJ; Choi GM; Jang HJ; Ma CH; Oh HS; Kim M; Eom DW
Oncol Lett; 2022 Oct; 24(4):373. PubMed ID: 36238847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]